

## Special Issue

# Drug-Repositioning Opportunities for Antiviral Therapy

### Message from the Guest Editor

In this Special issue, a special emphasis will be given to the investigation of drug repurposing as a novel antiviral strategy to combat emerging and re-emerging viral diseases. Drug repurposing, also known as redirecting, repurposing, repositioning, and re-profiling, is an alternative to the classical process of development of antivirals. This process can be very useful in emergencies, such as the one currently caused by Covid-19. The drug repurposing approach has identified some promising drug candidates for different viral diseases like Ebola, ZIKA, dengue, influenza, HIV, herpes simplex virus (HSV), CMV, and Covid-19 infections. This Special issue aims to explore drug repurposing as an approach to find candidate antiviral agents within a short span of time to overcome the challenges of drug development and the global threat of emerging and re-emerging viral infectious diseases. We welcome original research and comprehensive review articles presenting recent progress, challenges, and future perspectives of drug repurposing in antiviral drug discovery.

### Guest Editor

Prof. Dr. Graciela Andrei

Rega Institute, Department of Microbiology, Immunology & Transplantation, KU Leuven, Leuven, Belgium

### Deadline for manuscript submissions

closed (20 December 2020)



## Viruses

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.5**  
**CiteScore 7.7**  
**Indexed in PubMed**



[mdpi.com/si/42051](https://mdpi.com/si/42051)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).